Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 24, Issue 11, 2014, Pages 2486-2492

  Woo, Jimin ^a,b   Kim, Hyun Young ^a   Byun, Byung Jin ^a   Chae, Chong Hak ^a   Lee, Ji Young ^a,c   Ryu, Shi Yong ^a,c   Park, Woo Kyu ^a   Cho, Heeyeong ^a,b   Choi, Gildon ^a,b  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Chungnam National University   (South Korea)

Author keywords

EZH2; Histone methyltransferase; Tanshindiol; Tanshinone

Indexed keywords

ANTINEOPLASTIC AGENT; METHYLTRANSFERASE INHIBITOR; TANSHINDIOL B; TANSHINDIOL C; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; ABIETANE DERIVATIVE; ENZYME INHIBITOR; EZH2 PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE; POLYCOMB REPRESSIVE COMPLEX 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTONE METHYLATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; CONFORMATION; DRUG EFFECTS; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DITERPENES, ABIETANE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MOLECULAR CONFORMATION; POLYCOMB REPRESSIVE COMPLEX 2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899905767     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2014.04.010     Document Type: Article

References (11)

1. C.L. Peterson, and M.A. Laniel Curr. Biol. 14 2004 R546
2. C.J. Chang, and M.C. Hung Br. J. Cancer 106 2012 243
3. A. Chase, and N.C. Cross Clin. Cancer Res. 17 2011 2613
4. M.T. McCabe, H.M. Ott, G. Ganji, S. Korenchuk, C. Thompson, G.S. Van Aller, Y. Liu, A.P. Graves, A. Della Pietra III, E. Diaz, L.V. LaFrance, M. Mellinger, C. Duquenne, X. Tian, R.G. Kruger, C.F. McHugh, M. Brandt, W.H. Miller, D. Dhanak, S.K. Verma, P.J. Tummino, and C.L. Creasy Nature 492 2012 108
5. S.K. Knutson, N.M. Warholic, T.J. Wigle, C.R. Klaus, C.J. Allain, A. Raimondi, M. PorterScott, R. Chesworth, M.P. Moyer, R.A. Copeland, V.M. Richon, R.M. Pollock, K.W. Kuntz, and H. Keilhack Proc. Natl. Acad. Sci. U.S.A. 110 2013 7922
6. L. Zhou, Z. Zuo, and M.S. Chow J. Clin. Pharmacol. 45 2005 1345
7. M. Fronza, R. Murillo, S. Ślusarczyk, M. Adams, M. Hamburger, B. Heinzmann, S. Laufer, and I. Merfort Bioorg. Med. Chem. 19 2011 4876
8. X. Wang, S.L. Morris-Natschke, and K.-H. Lee Med. Res. Rev. 27 2007 133
9. C.-Y. Lee, H.-F. Sher, H.-W. Chen, C.-C. Liu, C.-H. Chen, C.-S. Lin, P.-C. Yang, H.-S. Tsay, and J.J.W. Chen Mol. Cancer Ther. 7 2008 3527
10. 3 centered on the ligand, each EZH2 inhibitor was then docked into the SAM substrate site using the Glide module in Standard Precision (SP) mode. The ligand interactions were illustrated by PyMol (W.L. DeLano The PyMol Molecular Graphics System 2002 DeLano Scientific San Carlos, CA, USA)
11. L. Luo, C.A. Parrish, N. Nevins, D.E. McNulty, A.M. Chaudhari, J.D. Carson, V. Sudakin, A.N. Shaw, R. Lehr, H. Zhao, S. Sweitzer, L. Lad, K.W. Wood, R. Sakowicz, R.S. Annan, P.S. Huang, J.R. Jackson, D. Dhanak, R.A. Copeland, and K.R. Auger Nat. Chem. Biol. 3 2007 722